{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:53:51Z","timestamp":1784238831357,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["No. 3\/2\/June- 2021\/Pg-Thesis-HRD (01)"],"award-info":[{"award-number":["No. 3\/2\/June- 2021\/Pg-Thesis-HRD (01)"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00520-025-09275-2","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:28:23Z","timestamp":1739960903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A group sequential response-adaptive randomized double-blinded clinical trial to evaluate the safety and efficacy of add-on olanzapine plus pregabalin for the prevention of chemotherapy-induced nausea and vomiting"],"prefix":"10.1007","volume":"33","author":[{"given":"Mathan Kumar","family":"Ramasubbu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Hota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj kumar","family":"Das Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dillip Kumar","family":"Parida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"9275_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00520-018-4131-3","volume":"26","author":"M Aapro","year":"2018","unstructured":"Aapro M (2018) CINV: still troubling patients after all these years. Support Care Cancer 26:5\u20139","journal-title":"Support Care Cancer"},{"key":"9275_CR2","first-page":"S259","volume":"23","author":"N Adel","year":"2017","unstructured":"Adel N (2017) Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care 23:S259\u2013S265","journal-title":"Am J Manag Care"},{"key":"9275_CR3","doi-asserted-by":"crossref","unstructured":"Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriyappa L, Jacob LA, Mallekavu SB, Dasappa L, Kiran PR, Sreevatsa A, Appachu S, Unnikrishnan V, Arroju V (2016) The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India Chemother Res Pract 2016: 3439707","DOI":"10.1155\/2016\/3439707"},{"key":"9275_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/14740338.2020.1724955","volume":"19","author":"P Bossi","year":"2020","unstructured":"Bossi P, Airoldi M, Aloe Spiriti MA, Antonuzzo A, Bonciarelli G, Campagna A, Cassano A, Murialdo R, Musio D, Silvano G (2020) A multidisciplinary expert opinion on CINV and RINV unmet needs and practical real-life approaches. Expert Opinion Drug Saf 19:187\u2013204","journal-title":"Expert Opinion Drug Saf"},{"key":"9275_CR5","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1007\/s00520-020-05977-x","volume":"29","author":"R Chow","year":"2021","unstructured":"Chow R, Chiu L, Herrstedt J, Aapro M, Lock M, DeAngelis C, Navari RM (2021) Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients. Support Care Cancer 29:4269","journal-title":"Support Care Cancer"},{"key":"9275_CR6","doi-asserted-by":"crossref","unstructured":"Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D (2018) Randomized placebo-controlled phase iii trial of fosaprepitant ondansetron dexamethasone (fond) versus fond plus olanzapine (fond-o) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens. FOND-O Trial Biol Blood Marrow Transplant. 24 2065\u20132071","DOI":"10.1016\/j.bbmt.2018.06.005"},{"key":"9275_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497\u2013503","journal-title":"Support Care Cancer"},{"key":"9275_CR8","first-page":"850794","volume":"2014","author":"A Demirhan","year":"2014","unstructured":"Demirhan A, Akkaya A, Tekelioglu UY, Apuhan T, Bilgi M, Yurttas V, Bayir H, Yildiz I, Gok U, Kocoglu H (2014) Effect of pregabalin and dexamethasone on postoperative analgesia after septoplasty. Pain Res Treat 2014:850794","journal-title":"Pain Res Treat"},{"key":"9275_CR9","first-page":"1","volume":"5","author":"S Dulal","year":"2019","unstructured":"Dulal S, Paudel BD, Neupane P, Shah A, Acharya B, Poudyal BS, Shilpakar R, Wood LA (2019) Randomized phase ii trial to compare the efficacy of haloperidol and olanzapine in the control of chemotherapy-induced nausea and vomiting in nepal j glob. Oncol 5:1\u20136","journal-title":"Oncol"},{"key":"9275_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0028-3908(01)00172-1","volume":"42","author":"K Fink","year":"2002","unstructured":"Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Gothert M (2002) Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42:229\u2013236","journal-title":"Neuropharmacology"},{"key":"9275_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s12630-014-0147-4","volume":"61","author":"RB George","year":"2014","unstructured":"George RB, McKeen DM, Andreou P, Habib AS (2014) A randomized placebo-controlled trial of two doses of pregabalin for postoperative analgesia in patients undergoing abdominal hysterectomy. Can J Anaesth 61:551\u2013557","journal-title":"Can J Anaesth"},{"key":"9275_CR12","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1213\/ANE.0000000000001404","volume":"123","author":"MC Grant","year":"2016","unstructured":"Grant MC, Betz M, Hulse M, Zorrilla-Vaca A, Hobson D, Wick E, Wu CL (2016) The effect of preoperative pregabalin on postoperative nausea and vomiting: a meta-analysis. Anesth Analg 123:1100\u20131107","journal-title":"Anesth Analg"},{"key":"9275_CR13","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.ctarc.2020.100278","volume":"26","author":"K Gupta","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP (2021) Chemotherapy-induced nausea and vomiting: pathogenesis recommendations and new trends. Cancer Treat Res Commun 26:100278","journal-title":"Cancer Treat Res Commun"},{"key":"9275_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre randomised double-blind placebo-controlled phase 3 trial. Lancet Oncol 21:242\u2013249","journal-title":"Lancet Oncol"},{"key":"9275_CR15","first-page":"22","volume":"24","author":"DA Hegarty","year":"2011","unstructured":"Hegarty DA, Shorten GD (2011) A Randomised placebo-controlled trial of the effects of preoperative pregabalin on pain intensity and opioid consumption following lumbar discectomy korean. J Pain 24:22\u201330","journal-title":"J Pain"},{"key":"9275_CR16","doi-asserted-by":"crossref","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study G (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol. 21: 4112\u20134119","DOI":"10.1200\/JCO.2003.01.095"},{"key":"9275_CR17","doi-asserted-by":"crossref","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH (2020) Antiemetics: asco guideline update 38: 2782\u20132797","DOI":"10.1200\/JCO.20.01296"},{"key":"9275_CR18","doi-asserted-by":"crossref","unstructured":"Ithimakin S, Theeratrakul P, Laocharoenkiat A, Nimmannit A, Akewanlop C, Soparattanapaisarn N, Techawattanawanna S, Korphaisarn K, Danchaivijitr P (2020) Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Support Care Cancer. 28: 5335\u20135342","DOI":"10.1007\/s00520-020-05380-6"},{"key":"9275_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00520-004-0755-6","volume":"13","author":"RM Navari","year":"2005","unstructured":"Navari RM, Einhorn LH, Passik SD, Loehrer PJ Sr, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a hoosier oncology group study. Support Care Cancer 13:529\u2013534","journal-title":"Support Care Cancer"},{"key":"9275_CR20","doi-asserted-by":"crossref","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 9: 188-195","DOI":"10.1016\/j.suponc.2011.05.002"},{"key":"9275_CR21","doi-asserted-by":"publisher","first-page":"628","DOI":"10.21037\/apm.2020.04.32","volume":"9","author":"RM Navari","year":"2020","unstructured":"Navari RM, Loprinzi CL (2020) Olanzapine is an effective antiemetic agent Ann. Palliat Med 9:628\u2013630","journal-title":"Palliat Med"},{"key":"9275_CR22","first-page":"141","volume":"14","author":"RM Navari","year":"2016","unstructured":"Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL (2016) Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting J Community Support. Oncol 14:141\u2013147","journal-title":"Oncol"},{"key":"9275_CR23","doi-asserted-by":"crossref","unstructured":"Park HS, Won HS, An HJ, Cho SS, Kim HH, Sun S, Ko YH, Shim BY (2021) Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy-induced nausea and vomiting: A prospective cohort study Cancer Med 10: 1057\u20131065","DOI":"10.1002\/cam4.3693"},{"key":"9275_CR24","doi-asserted-by":"crossref","unstructured":"Passik SD, Navari RM, Jung SH, Nagy C, Vinson J, Kirsh KL, Loehrer P (2004) A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study Cancer Invest 22: 383\u2013388","DOI":"10.1081\/CNV-200029066"},{"key":"9275_CR25","doi-asserted-by":"crossref","unstructured":"Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E, Jerzak KJ (2019) ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 27: 87\u201395","DOI":"10.1007\/s00520-018-4464-y"},{"key":"9275_CR26","doi-asserted-by":"crossref","unstructured":"Rossi C, Cruz F, del Giglio A, Rodrigues C, Castro SJAoO (2016) Phase II study of pregabalin for the prevention of chemotherapy induced nausea and vomiting 27: vi502","DOI":"10.1093\/annonc\/mdw390.17"},{"key":"9275_CR27","doi-asserted-by":"crossref","unstructured":"Santana TA, Trufelli DC, Matos LL, Cruz FM, Del Giglio A (2015) Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting. Support Care Cancer. 23: 213\u2013222","DOI":"10.1007\/s00520-014-2392-z"},{"key":"9275_CR28","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2147\/CMAR.S280995","volume":"13","author":"M Suehiro","year":"2021","unstructured":"Suehiro M, Kojima Y, Takahashi M, Ito Y, Keira T, Ikegawa K, Minatogawa H, Tsugawa K, Tanaka T (2021) Antiemetic efficacy of adding olanzapine 5 mg to aprepitant palonosetron and dexamethasone-sparing after day two for cancer patients receiving anthracycline and cyclophosphamide. Cancer Manag Res 13:1617\u20131624","journal-title":"Cancer Manag Res"},{"key":"9275_CR29","doi-asserted-by":"crossref","unstructured":"Sukauichai S, Ketkaew C, Othaganont N, Pichaya P, Promsuwan P (2022) Efficacy of olanzapine 5 mg versus 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting in patients receiving high emetic risk chemotherapy without neurokinin-1 receptor antagonist. Asian Pac J Cancer Prev. 23: 2137\u20132143","DOI":"10.31557\/APJCP.2022.23.6.2137"},{"key":"9275_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, Zhang D (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res CR 28:131","journal-title":"J Exp Clin Cancer Res CR"},{"key":"9275_CR31","doi-asserted-by":"crossref","unstructured":"Tienchaiananda P, Nipondhkit W, Maneenil K, Sa-Nguansai S, Payapwattanawong S, Laohavinij S, Maneechavakajorn J (2019) A randomized double-blind placebo-controlled study evaluating the efficacy of combination olanzapine ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. Annals of Palliative Medicine. 8: 372\u2013380","DOI":"10.21037\/apm.2019.08.04"},{"key":"9275_CR32","doi-asserted-by":"crossref","unstructured":"Uschner D, Schindler D, Hilgers R-D, Heussen N (2018) Randomizer: An r package for the assessment and implementation of randomization in clinical trials. J Stat Sof. 85: 1 - 22","DOI":"10.18637\/jss.v085.i08"},{"key":"9275_CR33","doi-asserted-by":"crossref","unstructured":"Wu X, Wu J, Tong G, Cheng B, Chen M, Yu S, He L, Li Z, Wang S (2020) Efficacy of olanzapine-triple antiemetic regimen in patients with gastrointestinal tumor and high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: A Retrospective Study Cancer Manag Res 12: 6575-6583","DOI":"10.2147\/CMAR.S254398"},{"key":"9275_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.breast.2020.01.005","volume":"50","author":"W Yeo","year":"2020","unstructured":"Yeo W, Lau TK, Li L, Lai KT, Pang E, Cheung M, Chan VT, Wong A, Soo WM, Yeung VT, Tse T, Lam DC, Yeung EW, Ng KP, Tang NL, Tong M, Suen JJ, Mo FK (2020) A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. The Breast 50:30\u201338","journal-title":"The Breast"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09275-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09275-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09275-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T01:28:30Z","timestamp":1742002110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09275-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["9275"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09275-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"19 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Ethics Committee of All India Institute of Medical Sciences, Bhubaneswar, approved the trial protocol. Written informed consent was obtained from all the participants. The trial was conducted in accordance with \u201cDeclaration of Helsinki\u201d and \u201cNational Ethical Guidelines for Biomedical and Health Research involving Human Participants (2017)\u201d by the Indian Council of Medical Research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"203"}}